Abstract
Ofatumumab represents a new, highly effective treatment for multiple sclerosis. It is a human monoclonal antibody targeted at CD20 surface antigen expressed on most cells of the B cell lineage and, to a small extent, T cells.
It differs from previously used CD20 depletors in several pharmacokinetic and pharmacodynamic properties. These allow safe subcutaneous administration with minimal adverse effects at a lower dose than other CD20 depletors - an initial dose of 20 mg by subcutaneous injection by patient self-administration at weeks 0, 1, 2, and from week 4 onwards at monthly intervals.
Due to the relatively faster repopulation of B cells, ofatumumab advantageously allows for faster discontinuation of therapy. Although similar depletion of cells in the periphery and lymph nodes has been demonstrated with other CD20 depletors administered at higher doses intravenously, the effect of ofatumumab and other CD20 depletors on B lymphocytes in the central nervous system is the subject of further studies.